Tracked deals
6
6 tracked deals across 2024.
Biotechnology Add-on Acquisitions in 2024
Buyer mix
Mixed buyer set
6 strategic · 5 pe
Top trend
Volume peaked in 2022
9 tracked deals announced in 2022.
Buyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Iron Path Capital | 2 | Private equity firm focused on building businesses in hea... | PE |
| VION Biosciences | 2 | Life-science platform company delivering specialty reagen... | Strategic (PE-backed) |
| Ajax Health | 1 | Healthcare-focused investment firm that deploys capital a... | Investor |
| Altaris, LLC | 1 | Healthcare-focused private investment firm that acquires ... | PE |
| Ampersand Capital Partners | 1 | Middle-market private equity firm focused on growth-orien... | PE |
| Hologic, Inc. | 1 | Medical technology company specializing in diagnostics, m... | Strategic |
| KKR | 1 | Global investment firm providing private equity capital a... | PE |
| Leinco Technologies | 1 | Manufacturer and supplier of primary/secondary antibodies... | Strategic (PE-backed) |
| Maverix Medical | 1 | Lung cancer platform company building diagnostic and inte... | Strategic (PE-backed) |
| eMolecules, Inc. | 1 | Provider of a chemical compound search-and-fulfillment pl... | Strategic (PE-backed) |
Acquisition Volume in Biotechnology Add-on in 2024 by Year
Last 8 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
December 24, 2024
- Buyer
- Altaris, LLC
- Target
- Advanced Therapies (U.S. and U.K. operations of WuXi AppTec's Advanced Therapies Unit), OXGENE
- Seller
- WuXi AppTec
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Addon
Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.
-
September 24, 2024
- Buyer
- eMolecules, Inc.
- Target
- Synple Chem AG
- Industry
- Biotechnology
- Location
- Zurich, Switzerland
- Type
- Addon
eMolecules, a San Diego-based provider of a chemical compound search-and-fulfillment platform and a portfolio company of Avista Healthcare Partners, has acquired Synple Chem AG, an automated chemical synthesis systems and services provider headquartered near Zurich, Switzerland. The acquisition adds Synple's automation technology and a virtual compound library of more than 7 trillion tractable compounds to eMolecules' existing offering, expanding its capabilities as a one-stop shop for compound procurement, management and automation for drug discovery customers.
-
September 3, 2024
- Buyer
- Leinco Technologies, Ampersand Capital Partners
- Target
- QED Biosciences
- Seller
- Genovis
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Addon
Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.
-
August 29, 2024
- Buyer
- VION Biosciences, Iron Path Capital
- Target
- Ansh Labs
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Addon
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Ansh Labs, an immunoassay development and reagent manufacturer based in Houston, Texas. The add-on expands VION's diagnostics capabilities — adding GMP IVD manufacturing and ISO 13485 certification — and broadens the platform's product and service offerings for clinical diagnostics, research, and pharmaceutical development.
-
August 22, 2024
- Buyer
- VION Biosciences, Iron Path Capital
- Target
- Echelon Biosciences
- Seller
- Bert V. Israelsen
- Industry
- Biotechnology
- Location
- Utah, United States
- Type
- Addon
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Salt Lake City-based Echelon Biosciences, a specialist supplier of lipid-based excipients and lipid nanoparticles. The add-on strengthens VION's capabilities in lipid synthesis and lipid nanoparticle technology to support mRNA and gene-therapy development and advances the platform toward drug manufacturing while keeping Echelon’s leadership and operations intact.
-
March 29, 2024
- Buyer
- Maverix Medical, Ajax Health, KKR, Hologic, Inc.
- Target
- Cirrus Bio
- Industry
- Biotechnology
- Location
- United States
- Type
- Addon
Maverix Medical, a lung cancer platform backed by Ajax Health, KKR, and Hologic, has acquired Cirrus Bio to form the foundation of a new diagnostics division, Maverix Dx. Cirrus Bio's multiomic diagnostic capabilities and its founders, David Mallery (CEO) and Scott Morris (CSO), will lead Maverix Dx as the platform pursues further diagnostic product development and M&A.
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in Pennsylvania
Biotechnology Acquisitions in California
Biotechnology Acquisitions in Texas
Biotechnology Acquisitions in Utah
Add-on Acquisitions in 2024